Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib in newly diagnosed Stage I-IIIC TNBC or HER2+ breast cancer
NCT04142554Phase 1Withdrawn
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of parsaclisib in breast cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Minimum effective dose of parsaclisib at 2 weeks. Planned start Jun 2020; status: withdrawn.
02
Drugs
parsaclisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04142554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142554.